echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ASCO 2021: Fate's iPSC-derived NK cell clinical data is active

    ASCO 2021: Fate's iPSC-derived NK cell clinical data is active

    • Last Update: 2021-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recent popular reports from Yimaike ★ Invitation to the event2021 Oncolytic Virus Drug Development Forum is about to open in Shanghai ★ The financing has been hundreds of millions in half a year, and the oncolytic virus has entered the fast laneYimai New Observation Click on the picture and register now June 9, 2021 /Healthcare News eMedClub News/--Fate recently announced the results of a multi-dose phase I clinical trial of FT516 at the 2021 American Society of Clinical Oncology (ASCO) annual meeting held on the weekend to study FT516 as a treatment for acute myeloid leukemia Monotherapy, combined with CD20 targeting monoclonal antibody to treat advanced B-cell lymphoma (NCT04023071)
    .

    The results showed that FT516 was active in patients who had undergone a lot of pretreatment and was well tolerated
    .

    ▲ Interim data from the FT516 Phase I relapsed/refractory ALL study (picture source: fate) FT516 is the company's general-purpose, ready-made natural killer (NK) cell candidate product, which is an engineered clone of induced pluripotent stem cells (iPSC) Department of development
    .

    FT516 is designed to maximize antibody-dependent cytotoxicity to destroy antibody-coated cancer cells
    .

    The clinical report showed that 8 of the 11 patients who could be studied achieved objective remission, and 6 of them achieved complete remission
    .

    Eight of these 11 patients had aggressive B-cell lymphoma, and four of them had previously received autologous CD19 and CAR-T cell therapy
    .

     The report specifically highlighted a case of "triple-hit, high-grade B-cell lymphoma with MYC, BCL2, and BCL6 gene rearrangements
    .
    "
    Except for autologous CD19 and CAR-T cell therapy, the trial patients were ineffective to all previous therapies
    .

    After the first treatment cycle of FR516, the patient achieved complete remission, all metabolically active diseases were resolved, and the size of the target lesion was reduced by 85%
    .

     At the data cutoff date of March 11, the patient completed the second FT516 treatment cycle, after which the response assessment continued to show a complete response
    .

    ➤ The emergence of iPSC-derived cell therapy The application of immune checkpoint inhibitors (ICI) has made tumor immunity and cell therapy flourish
    .

    However, with the deepening of research, people have found that there are many subjects who have no obvious effect on ICI treatment or who have relapsed later
    .

    The development of this field has encountered a bottleneck
    .

    However, scientists have discovered in clinical trials that adoptive transfer of NK cells has the inherent potential to overcome many of these ICI resistance mechanisms
    .

    NK cell treatment methods are beginning to gain attention
    .

    In 2018, Fate broke through technical barriers, developed FT500 and obtained FDA clinical research approval
    .

    This is also the first iPSC-derived cell therapy approved for research
    .

    FT500 will be combined with checkpoint inhibitor (ICI) for the treatment of advanced solid tumors
    .

    Since then, with the improvement of the induced pluripotent stem cell (iPSC) product platform and the accumulation of technology, FATE has launched a number of clinical NK cell project research
    .

     For more details, please click the QR code below to read the reference materials: 1.
    https:// from-lymphoma-study/YiMike has always been committed to original news reports such as cutting-edge technology, industry trends, industry insights, etc.
    of bio-innovative drugs.
    The high-end matrix users of all media have reached 160,000+, of which industrial users accounted for more than 50%.
    Research and clinical About 30% of users, and more than 5% of users of investment institutions
    .

    In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.